Successful antiviral therapy for chronic hepatitis C in a patient after surgery for hepatocellular carcinoma (a clinical observation)
https://doi.org/10.23873/2074-0506-2011-0-1-43-47
Abstract
The paper describes a case of successful treatment for chronic viral hepatitis C after surgery for hepatocellular carcinoma developing in the presence of evolved compensated hepatic cirrhosis. It also gives current approaches to choosing antiviral therapy and estimates its possibilities in patients with different surgical options for hepatocellular carcinoma.
About the Authors
I. G. Nikitin
N.I. Pirogov Russian State Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
I. E. Baikova
N.I. Pirogov Russian State Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
L. M. Gogova
N.I. Pirogov Russian State Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
V. M. Volynkina
N.I. Pirogov Russian State Medical University, Russian Agency for Health Care
Russian Federation
Russian Federation
P. O. Bogomolov
Hepatology Center, Moscow Regional Clinical Research Institute
Russian Federation
Russian Federation
O. S. Kuzmina
Hepatology Center, Moscow Regional Clinical Research Institute
Russian Federation
Russian Federation
A. L. Pylev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
I. V. Sagaidak
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Yu. I. Patyutko
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Ghany M.G., Strader D.B., Thomas D.L. et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
2. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
3. McHutchinson J.G., Lawitz E.J.,Schiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
4. Pegintron. Summary of Product Characteristics. Bruxelles, Belgium: SP Europe.
5. Jensen D.M., Freilich B., Andreone P. et al. Pegylated interferon alfa-2a (40kDa) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kDa)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology 2007;46:291A.
6. Ferenci P., Freid M.W., Schiffman M.L. et al. Predicting sustained virological responces in chronic hepatitis C patients treated with pegylated interferon alfa-2a (40kDa)/ribavirin. J Hepatol 2006;43:425-33.
7. Sanchez-Tapias J.M., Diago M.,Escartin P. et al. Peginterferon alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
8. Freid M., Jensen D., RodriguezTorres M. et al. Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40kDa) (PEGASYS) plus ribavirin (RBV) (COPEGUS) in patients with "difficult-to-cure" characteristics. Hepatology 2006;44:314A.
9. Ferenci P, Laferl H., Scherzer T.M. et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
10. Ge D.L., Fellay J., Thompson A.J. et al. Genetic variation in ILB28 predicts hepatitis C treatment -induced viral clearance. Nature 2009;469:399-401.
11. Tanaka Y., Nishida N., Sugiama M. et al. Genome-wide association of ILB28 with response to pegylated interferon-alfa and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:110-09.
12. Jensen D.M., Marcellin P., Freilich B. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alfa2b: a randomized trial. Ann Int Med 2009;15:528-40.
13. Bacon B.R., Shiffman M.L.,Everson G.T. et al. Prolonged therapy of advanced chronic hepatitis C with daily interferon alacon-1/ribavirin after non-response to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009;49:1838-46.
14. Clinical Dillemas in viral liver disease.Foster G., Rajender K. (eds). Wiley-Blackwell, 2011.
15. Bosch F.X., Ribes J., Diaz M. et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:5-16.
16. Kubo S., Nishigushi S., Hirogashi K. et al. Effects of long-term postoperative interferon-alfa therapy on intrahepatic reccurence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Int Med 2001;134:963-67.
17. Shen Y.C., Hsu C., Chen L.T. et al. Adjuvant interferon therapy after curative for hepatocellular carcinoma (HCC): A metaregression approach. J Hepatol 2010.
Review
For citations:
Nikitin I.G., Baikova I.E., Gogova L.M., Volynkina V.M., Bogomolov P.O., Kuzmina O.S., Pylev A.L., Sagaidak I.V., Patyutko Yu.I. Successful antiviral therapy for chronic hepatitis C in a patient after surgery for hepatocellular carcinoma (a clinical observation). Transplantologiya. The Russian Journal of Transplantation. 2011;(1):43-47. (In Russ.) https://doi.org/10.23873/2074-0506-2011-0-1-43-47
Views:
602
Email this article 